PROTAC ER Degraders in ER+/HER2- MBC After ET: Novel ER-Targeting Therapy Data and a Look to the Future

Watch this video to gain expert insights on the current clinical trial research investigating novel PROTAC ER degrader agents for patients with ERHER2 MBC after disease progression on endocrine therapy

• Provider:Clinical Care Options
• Activity Link: https://clinicaloptions.com/CE-CME/oncology/protacs-data-in-erher2-mbc/32334-61984
• Start Date: 2024-11-14 06:00:00
• End Date: 2024-11-14 06:00:00
• Credit Details: AMA PRA Category 1 Credit™️: 0.25 hours
• Commercial Support: Source: Pfizer (Any division) - Amount: 55000.0 - Is Kind Support: False
• Activity Type: Enduring Material
• CME Finder Type: Online Learning
• Fee to Participate: No, it's free
• Measured Outcome: Learner Knowledge, Learner/Team Competence
• Provider Ship: Directly Provided
• Registration: Open to all

Subscribe

Login

Notify of

new follow-up comments new replies to my comments

Label

{} [+]

Name*

Email*

Website

Label

{} [+]

Name*

Email*

Website

0 Comments

Oldest

Newest Most Voted

Inline Feedbacks

View all comments